1. Home
  2. PTMN vs ACTU Comparison

PTMN vs ACTU Comparison

Compare PTMN & ACTU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PTMN
  • ACTU
  • Stock Information
  • Founded
  • PTMN 2006
  • ACTU 2015
  • Country
  • PTMN United States
  • ACTU United States
  • Employees
  • PTMN N/A
  • ACTU N/A
  • Industry
  • PTMN Finance: Consumer Services
  • ACTU
  • Sector
  • PTMN Finance
  • ACTU
  • Exchange
  • PTMN Nasdaq
  • ACTU NYSE
  • Market Cap
  • PTMN 113.0M
  • ACTU 135.0M
  • IPO Year
  • PTMN N/A
  • ACTU 2024
  • Fundamental
  • Price
  • PTMN $12.68
  • ACTU $10.55
  • Analyst Decision
  • PTMN Hold
  • ACTU Strong Buy
  • Analyst Count
  • PTMN 1
  • ACTU 1
  • Target Price
  • PTMN $14.00
  • ACTU $20.00
  • AVG Volume (30 Days)
  • PTMN 52.0K
  • ACTU 68.7K
  • Earning Date
  • PTMN 05-08-2025
  • ACTU 05-21-2025
  • Dividend Yield
  • PTMN 17.06%
  • ACTU N/A
  • EPS Growth
  • PTMN N/A
  • ACTU N/A
  • EPS
  • PTMN N/A
  • ACTU N/A
  • Revenue
  • PTMN $58,024,000.00
  • ACTU N/A
  • Revenue This Year
  • PTMN N/A
  • ACTU N/A
  • Revenue Next Year
  • PTMN $4.14
  • ACTU N/A
  • P/E Ratio
  • PTMN N/A
  • ACTU N/A
  • Revenue Growth
  • PTMN N/A
  • ACTU N/A
  • 52 Week Low
  • PTMN $11.60
  • ACTU $5.51
  • 52 Week High
  • PTMN $20.84
  • ACTU $11.73
  • Technical
  • Relative Strength Index (RSI)
  • PTMN 50.82
  • ACTU N/A
  • Support Level
  • PTMN $12.00
  • ACTU N/A
  • Resistance Level
  • PTMN $12.80
  • ACTU N/A
  • Average True Range (ATR)
  • PTMN 0.28
  • ACTU 0.00
  • MACD
  • PTMN 0.16
  • ACTU 0.00
  • Stochastic Oscillator
  • PTMN 82.64
  • ACTU 0.00

About PTMN Portman Ridge Finance Corporation

Portman Ridge Finance Corp Inc is a non-diversified closed-end investment company. The company originates, structures, and invests in secured term loans, bonds or notes, and mezzanine debt primarily in privately-held middle market companies but may also invest in other investments such as loans to publicly traded companies, high-yield bonds, and distressed debt securities. The company's investment objective in the Debt securities portfolio is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt, and selected equity investments in privately-held middle market companies.

About ACTU ACTUATE THERAPEUTICS INC

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Share on Social Networks: